- Home
- NKSH vs ATAI Comparison
NKSH vs ATAI Comparison
Compare NKSH & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKSH
- ATAI
- Stock Information
- Founded
- NKSH 1891
- ATAI 2018
- Country
- NKSH United States
- ATAI Germany
- Employees
- NKSH N/A
- ATAI N/A
- Industry
- NKSH Major Banks
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- NKSH Finance
- ATAI Health Care
- Exchange
- NKSH Nasdaq
- ATAI Nasdaq
- Market Cap
- NKSH 182.9M
- ATAI 214.8M
- IPO Year
- NKSH N/A
- ATAI 2021
- Fundamental
- Price
- NKSH $30.80
- ATAI $1.26
- Analyst Decision
- NKSH Strong Buy
- ATAI Strong Buy
- Analyst Count
- NKSH 1
- ATAI 4
- Target Price
- NKSH $38.00
- ATAI $9.00
- AVG Volume (30 Days)
- NKSH 14.4K
- ATAI 1.3M
- Earning Date
- NKSH 10-24-2024
- ATAI 11-13-2024
- Dividend Yield
- NKSH 4.92%
- ATAI N/A
- EPS Growth
- NKSH N/A
- ATAI N/A
- EPS
- NKSH 1.44
- ATAI N/A
- Revenue
- NKSH $43,450,000.00
- ATAI $331,000.00
- Revenue This Year
- NKSH N/A
- ATAI $93.15
- Revenue Next Year
- NKSH $14.93
- ATAI N/A
- P/E Ratio
- NKSH $21.26
- ATAI N/A
- Revenue Growth
- NKSH N/A
- ATAI N/A
- 52 Week Low
- NKSH $26.50
- ATAI $1.03
- 52 Week High
- NKSH $35.93
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- NKSH 47.99
- ATAI 38.50
- Support Level
- NKSH $30.80
- ATAI $1.47
- Resistance Level
- NKSH $32.03
- ATAI $1.69
- Average True Range (ATR)
- NKSH 0.87
- ATAI 0.11
- MACD
- NKSH -0.08
- ATAI -0.05
- Stochastic Oscillator
- NKSH 42.01
- ATAI 0.95
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.